London scientists have made a breakthrough fighting the scourge of multiple sclerosis, fine-tuning MRIs to detect the disease before it ravages its victims.
“This could be a real game-changer,” said Dr. Bruce Bebo, who this year will decide how to invest $50 million in research raised by the National MS Society in the United States.
Bebo marvelled Thursday from afar at the work of a London research team headed by Dr. Ravi Menon that’s aimed at what has been an elusive target — finding and treating MS before it causes physical and cognitive impairment.
The challenge is especially pressing in Canada, where MS rates are the highest in the world — nine times higher than the world average.
Neurologists have long used MRIs to diagnose MS by showing damage to the protective sheath that insulates the body’s central nervous system.
Now, London researchers have fine-tuned a high-powered MRI to actually measure the amount of damage to that protective sheath —called myelin — as well as the deposits of iron typically found with the disease.
The team from Western University perfected the scans first on rats in a study published this month in the journal Proceedings of the National Academy of Sciences.
“It’s a huge step (forward),” Menon told The Free Press.
They then tested it on people, and though that study won’t be published until January, preliminary data showed that damage might be pinpointed
long before patients are traditionally diagnosed, potentially before they had suffered any ill effects.
“It’s really the holy grail, being able to track myelin,” Bebo said.
Though it’s not practical or affordable to screen everyone for MS using an MRI, research is underway to identify those most at risk from the disease. Some day, that work might lead to simpler tests such as a blood test to find those more at-risk who could then be scanned before the onset of symptoms, Bebo said.
In the meantime, more precise MRIs may help people already being treated for the disease with conventional drugs that suppress their immune system — it’s the immune system that attacks the myelin.
That treatment is by trial and error: If patients continue to deteriorate, doctors switch medications. Menon’s MRIs might help doctors switch away from failing medications before the damage occurs, Bebo said.
New research is aimed at reversing the damage to myelin, a task that may deliver even greater benefit if MS is discovered early, he said.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Primary Progressive Multiple Sclerosis Treatment Market 2020 Analysis report with Cross-Channel, Opportunities, Upturn Growth by 2026on June 29, 2020 at 3:20 am
The report provides rational insights along with historical and forecast data to aid in better understanding of ...
- Multiple Sclerosis Drugs Market 2020 Top Manufacturers, Industry Share, Size, Regional Analysis, Types and Applications and Forecasts to 2025on June 26, 2020 at 4:54 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Multiple Sclerosis Drugs ...
- BRIEF-Geneuro Enrolls First Patient In Temelimab Phase 2 Multiple Sclerosis Trialon June 24, 2020 at 10:45 pm
GENEURO ENROLLS FIRST PATIENT IN TEMELIMAB PHASE 2 MULTIPLE SCLEROSIS TRIAL IN COLLABORATION WITH THE KAROLINSKA INSTITUTET’S ACADEMIC SPECIALIST CENTER (ASC) * GENEURO SA - ONE-YEAR SINGLE CENTER ...
- New MyMSTeam Resource Center Educates People Living With Multiple Sclerosis On The Importance of Treatment and Adherenceon June 24, 2020 at 9:30 am
Today, MyHealthTeams and EMD Serono, through their MS-LINK initiative, announced the launch of the Treatment and Adherence Resource Center within MyMSTeam, the social network for (MS). The ...
- Disease-modifying therapy aids cognition in multiple sclerosison June 24, 2020 at 2:19 am
A new meta-analysis indicates that multiple sclerosis disease-modifying therapies (DMTs) have positive effects on cognition. High-efficacy and medium-efficacy DMTs apparently had comparable cognitive ...
- Global Multiple Sclerosis Market (Covid 19 Update) Emerging Technology, Investor Analysis and Worldwide Forecast till 2027on June 18, 2020 at 12:27 pm
Global Multiple Sclerosis Market, By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others), Diagnosis (Magnetic Resonance Imaging (MRI) Scans, Simple Electrical Stimulation Tests, ...
- Biogen Loses Court Decision to Mylan Over Multiple Sclerosis Drugon June 18, 2020 at 12:08 pm
A U.S. District Court judge rules that Mylan proved claims for Biogen’s patent for Tecfidera are invalid for 'lack of written description.' ...
- Biogen Can Bounce Back from Multiple-Sclerosis Blowon June 18, 2020 at 9:31 am
The biotech company has suffered a surprise blow to its blockbuster multiple sclerosis franchise. It has a chance to recover, but investors should expect a bumpy ride.
- Multiple Sclerosis Drugs Market: New Multiple Sclerosis Medication in Research Pipeline Promises Better Resultson June 18, 2020 at 8:46 am
Introduction In terms of revenue, the multiple sclerosis drugs market is projected to expand at a CAGR of ~6% during the ...
- Insufficient evidence for cognitive efficacy of drug treatments in multiple sclerosison June 17, 2020 at 7:53 pm
Researchers at Kessler Foundation conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction ...
via Bing News